Improvements in Glycemic Control Achieved by Altering the t_max Setting in the iLet^® Bionic Pancreas When Using Fast-Acting Insulin Aspart: A Randomized Trial.

ABSTRACT:

Introduction

We investigated the safety of, and glucose control by, the insulin-only configuration of the iLet^® bionic pancreas delivering fast-acting insulin aspart (faster aspart), using the same insulin-dosing algorithm but different time to maximal serum drug concentration (t_max) settings, in adults with type 1 diabetes.

Methods

We performed a single-center, single-blinded, crossover (two 7-day treatment periods) escalation trial over three sequential cohorts. Participants from each cohort were randomized to a default t_max setting (t₆₅ [t_max = 65 min]) followed by a non-default t_max setting (t₅₀ [t_max = 50 min; cohort 1], t₄₀ [t_max = 40 min; cohort 2], t_30</

SUBMITTER: Russell SJ 

PROVIDER: S-EPMC8266971 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature